The CLIP1–LTK Fusion Is an Oncogenic Driver of NSCLC

Article navigation

Research Watch| February 09 2022

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2022

American Association for Cancer Research.

Cancer Discov (2022) 12 (2): 286.

Abstract

The CLIP1–LTK fusion drives advanced non–small cell lung cancer (NSCLC) and represents a therapeutic target.

2022

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.